SITC 2025 Bispecific Post-Conference Report
Key Insights Included:
- 62 bispecific-related abstracts identified (84% preclinical)
- 70 drugs mapped, including 18 first-time disclosures at SITC 2025.
- TCR bispecifics and CD3-targeting T-cell engagers drove most new additions.
- Trispecific T-cell engagers are gaining momentum in the pipeline.
- Slide-by-slide summaries covering all clinical and preclinical abstracts.
Get the full report – download now to explore the science and strategy behind these key developments.
You May Also Be Interested In…
Learn More About Bispecific
What is Beacon Bispecific?
- The Most Comprehensive Way to Search the Bispecific Drug Development Landscape: Unique search ontologies based on Bispecific drug and trial characteristics
- Market Leading Approach to Bispecific Preclinical & Clinical Data Curation: Manual curation of key Bispecific research and development data points Bispecific research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Bispecific company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
